Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Panagiotis A KonstantinopoulosSu-Chun ChengElizabeth K LeeAlexandre Andre Balieiro Anastacio da CostaDoga C GulhanAndrea E Wahner HendricksonBose S KochupurakkalDavid L KolinElise C KohnJoyce F LiuRichard T PensonElizabeth H StoverJennifer CurtisHannah SawyerMadeline PolakDipanjan ChowdhuryAlan D' AndreaAnniina FärkkiläGeoffrey I ShapiroUrsula A MatulonisPublished in: JCO precision oncology (2024)
The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.
Keyphrases